Nanomedicines have proven themselves as a viable formulation strategy given their global impact during the COVD-19 pandemic. The trajectory of this field is expected to reach new heights in the years to come, making it even more important to assess how it arrived at its current state. When considering the FDA-approved nanomedicines, specifically the organic lipid-and polymer-based products, the composition and nanotechnology underlying each of these categories of nanomedicines are relatively similar. This is contrasted with the current formulation research landscape, which seems to emphasize complexity to achieve novelty as opposed to considering feasibility of clinical translation. With the current approach also based on trial-and-error and variable reporting standards, reproduction of these formulations is a challenge. Automation, coupled with ML, has enormous potential to accommodate and facilitate the continued development of nanomedicines. By integrating methods of generating highquality data and processing this data with robust computational techniques, it is possible to achieve more accurate, reproducible, and efficient workflows that support the end goal of producing clinically relevant nanomedicines.